Login to get immediate access to this content.
LoginSpeaker: Hans Gelderblom , Netherlands
Abstract discussed:
- LBA78 - Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 1-year follow-up from the MOTION phase 3 trial: Watch the presentation from ESMO 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published October 2024